Searched for
PHARMATRAC
India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...- ORS sales melt in March after govt's stricter labelling normsIndia’s oral rehydration solution (ORS) market has declined after regulatory action restricted the labelling of sugary drinks as ORS, affec...
- Quadria, PE funds eye stake in Samarth Lifesciences; deal may value firm at Rs 4,500 croreQuadria Capital is eyeing a strategic acquisition of a majority interest in Samarth Lifesciences, a move that could value the transaction a...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Slimmer price tag helps Wegovy sales gain weightNovo Nordisk has slashed Wegovy prices in India by nearly 40 percent. This move has dramatically increased sales volume by 70 percent in No...
- Respiratory drug sales peak in November amid worsening AQIIndia's air quality decline is boosting medicines for breathing problems. The respiratory drug market grew 8% last month, a rise from previ...
- Under the scanner, yet generic cough syrups hit shelvesWorry is spreading regarding the multitude of cough syrup brands circulating in India, with alarming revelations of toxic diethylene glycol...
- More patients can access key drugs after GST rate cutsRecent GST rate cuts on critical medicines are set to significantly reduce costs for treatments of conditions like multiple myeloma, lung c...
- Mounjaro crosses Rs 50 cr in India in 90 days as Wegovy joins frayMounjaro, Eli Lilly's weight-loss drug, witnessed a massive sales jump in India since March. Sales reached ₹26 crore in June. Wegovy from N...
- Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demandEli Lilly's Mounjaro has seen a positive reception in India, capturing significant sales and market interest since its launch in March. The...
- Mercury soars, and so do sales of rehydration drinks in IndiaIndia is experiencing a surge in demand for dehydration-preventing drinks due to the intense heatwave. Electral sales have jumped 27% in Ma...
- Global companies account for 60% of Indian vaccine sales by valueIndia's vaccine market is steadily recovering after the impact from Covid-19 and multinationals are back to slowly gaining traction, sugges...
- Pharma market grows 9.5% in JanuaryThe Indian pharmaceutical market (IPM) saw a robust growth of 9.5% in January with all major therapy areas recording double-digit growth. A...
- Government prohibits 328 fixed dose combinationsThe ban is effective immediately and may shave off over Rs 1,500 crore from India’s Rs 1.18 lakh crore pharmaceutical industry
- Unichem Labs under regulator scanner for launching blood pressure medicines without price approvalAccording to NPPA, Unichem launched these medicines over four years before it applied to the regulator for price fixation.
- Biocon shares gains on cancer drug launchA biosimilar is a near copy of an original complex biologic drug.
- Popular antacid samples fail quality tests, company claims they were counterfeitsThe Pantocid and Pantocid DSR tested by CDSCO were not manufactured by Sun Pharma, the official spokesperson for the Mumbai-based drug make...
- Cipla aims to reach $1bn India sales through tie-upsCipla has stepped up launch plans in areas like respiratory, dermatology, cardiovascular and urology, which will help speed up its India gr...
- Domestic Pharma Growth Improves for the month of MaySequentially, the domestic pharma industry staged an improvement for the month of May. At 9.9%, according to data compiled by PharmaTrac
- Poor growth of anti-infective segment remains a concern for pharmaceutical sectorThe latest growth numbers released for the month of February 2013 do not hold good news for the Indian pharma industry.
Load More
